A new study shows a product based on activated charcoal protects the gut microbiome in patients taking antibiotics. The Phase I clinical trial showed promising results. The study reported in the Journal of Infectious Diseases compared DAV132, with a placebo.
“DAV132 was highly effective to protect the gut microbiome of moxafloxacin-treated healthy volunteers and may constitute a clinical breakthrough by preventing adverse health consequences of a wide range of antibiotic treatments,” Dr. Jean de Gunzburg of Da Volterra in Paris, the company developing DAV132.
